Optic Disc Edema and Retinal Abnormality Secondary to Dasatinib Treatment in a CML Patient

Identifier 20170402_nanos_posters_027
Title Optic Disc Edema and Retinal Abnormality Secondary to Dasatinib Treatment in a CML Patient
Creator Reut Singer; Anatoly Nemets; Eyal Aloni
Affiliation (RS) (AN) (EA) Barzilai Medical Center, Ness Ziona, Israel
Subject Diagnostic Tests (ERG, VER, OCT, HRT, mfERG, etc); Eyelid & Adnexal Disease
Description Dasatinib (Sprysel) is a new second generation oral Bcr-Abl tyrosine kinase inhibitor, approved for first line treatment of patients with chronic myelogenous leukemia (CML). According to phase 1 and 2 studies published to date ophthalmological secondary effects of dasatinib, are practically non-existent or trivial. Resent literature case report suggest the possibility of secondary optic neuropathy caused by the drug.
Date 2017-04-02
Language eng
Format application/pdf
Type Text
Source 2017 North American Neuro-Ophthalmology Society Annual Meeting
Relation is Part of NANOS 2017: Poster Presentations
Collection Neuro-Ophthalmology Virtual Education Library: NANOS Annual Meeting Collection: https://novel.utah.edu/collection/nanos-annual-meeting-collection/
Publisher North American Neuro-Ophthalmology Society
Holding Institution Spencer S. Eccles Health Sciences Library, University of Utah
Rights Management Copyright 2017. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright
ARK ark:/87278/s6w9949s
Setname ehsl_novel_nam
ID 1272682
Reference URL https://collections.lib.utah.edu/ark:/87278/s6w9949s